期刊文献+

肿瘤坏死因子受体相关因子6在骨髓瘤细胞中的表达

The expression of TRAF6 in multiple myeloma cells and the relationship with myeloma markers
下载PDF
导出
摘要 目的:观察多发性骨髓瘤细胞中TRAF6的表达水平及其与患者各项临床指标的关系。方法:采用RT-PCR及Western Blot技术检测骨髓瘤细胞株及患者骨髓单个核细胞中TRAF6的表达状况,并与患者外周血乳酸脱氢酶(LDH)、β2-微球蛋白(β2M)、白蛋白(ALB)表达水平作相关性分析。结果:(1)TRAF6在骨髓瘤细胞株及患者骨髓单个核细胞中的表达水平均高于正常对照组。(2)患者骨髓单个核细胞TRAF6蛋白含量与β2M表达成正相关(r=0.882,P<0.01),与ALB表达成负相关(r=-0.846,P<0.01),与LDH表达无相关(r=0.245,P>0.05)。结论:TRAF6在骨髓瘤细胞中表达增高,且与患者β2M、ALB的表达水平相关。 Objective:To determine the expression of TRAF6 in multiple myeloma(MM) cell lines and to observe the level of TRAF6 in bone marrow mononuclear cells of MM patients and the relationship between tumor markers in patients.Methods:By RT-PCR and Western Blot the expression of TRAF6 in multiple myeloma cell lines of KM3,U266 and RPMI8226 was detected.The expression of TRAF6 in bone marrow mononuclear cells of MM patients and controls was determined.The correlativity of the expressions of LDH,β2M and albumin was observed by testing peripheral blood and compared with the expression of TRAF6 in BM mononuclear cells.Results:(1)The levels of TRAF6 in myeloma cell lines and in myeloma BM mononuclear cells were higher than in the control group.(2)The levels of TRAF6 in myeloma BM mononuclear cells were positively correlated with its peripheral β2M(P0.01),and negatively correlated with its peripheral albumin(P〈0.01).But there was no significant correlation with LDH(P0.05).Conclusion: The expression of TRAF6 in myeloma cells was higher than normal and was positively correlated with peripheral β2M,and negatively correlated with peripheral albumin.
出处 《交通医学》 2013年第3期224-226,230,共4页 Medical Journal of Communications
基金 国家自然科学基金青年科学基金资助项目(81201857) 江苏省六大人才高峰资助计划(第七批)(2010-WS-037)
关键词 多发性骨髓瘤 肿瘤坏死因子受体相关因子6 逆转录聚合酶链反应 WESTERN BLOT法 Multiple myeloma(MM) Tumor necrosisfactor receptor-associated factor 6(TRAF6) Reverse transcriptate polymerase chain reaction(RT-PCR) Western Blot
  • 相关文献

参考文献11

  • 1Engel D, Seijkens T, Poggi M, et al.The immunobiol-ogy of CD154-CD40-TRAF interactions in atherosclerosis[J]. Semin Immuno, 2009, 21(5): 308-312.
  • 2Arch RH, Gedrich RW, Thompson CB.Tumor necrosis factor receptor - associated factors (TRAFs)- a family of adapter proteins that regulateslife and death [J]. Genes Dev,1998,12 (18): 2821-2830.
  • 3Ye H, Arron JR, Lamothe B, et al. Distinct molecular mecha- nism for initiating TRAF6 signalling[J]. Nature,2002,418 (6896):443-447.
  • 4Hongming H, Jian H.Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6[J]. Leuk Res,2009,33(1): 115-122.
  • 5Aderem A. Role of Toll-like receptors in inflammatory re- sponse in macrophages[J]. Crit Care Med,2001,29(7 Suppl): S16-S18.
  • 6Muggia FM. Overview of cancer-related hypercalcemia: epi- dermiologyand etiology[J]. Semin Onco1,1990,17 ( 2 suppl 5) : 3-9.
  • 7Chung JY,Park YC,Ye H, et al. All TRAFs are notcreated e-.qual: common and distinct molecular mechanisms of TRAF- mediated signal transduction[J].J Cell Sci,2002,115(Pt 4): 679-688.
  • 8Arch RH, Gedrich RW,Thompson CB.Tumor necrosis factor receptor-associated factors(TRAFs)-a family of adapter pro- teins that regulates life and death[J]. Genes Dev,1998,12(18): 2821 -2830.
  • 9Jeong S, Cho IR, An WG, et al. STP- All, an oneoprotein of Herpesvirus saimiri augments both NF- kappaB and AP- 1 transcription activity through TRAF6[J]. Exp Mol Med, 2007, 39(1): 56-64.
  • 10邓书会,徐燕,麦玉洁,王亚非,赵耀中,邹德慧,邱录贵.112例多发性骨髓瘤患者ISS分期分析及与DS分期、IFM分期的比较[J].中华血液学杂志,2008,29(4):217-221. 被引量:11

二级参考文献7

  • 1陶中飞,傅卫军,陈玉宝,袁振刚,王东星,侯健.206例多发性骨髓瘤预后因素分析及分期评价[J].癌症,2006,25(4):461-464. 被引量:44
  • 2Greipp PR, Miguel JS, Durie BG, et al. International staging system for multiple myeloma. J Clin Oneol, 2005, 23:3412-3420.
  • 3Sagaster V, Kaufmann H, Odelga V, et al. Chromosomal abnormalities of young multiple myeloma patients ( <45 yr) are not different from those of other age groups and are independent of stage according to the International Staging System. Eur J Haematol, 2007, 78:227-234
  • 4Augustson BM, Begum G, Dunn JA, et al. Early mortality after diagnosis of multiple myeloma : analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 Medical Research Council Adult Leukaemia Working Party. J Clin Oncol, 2005, 23:9219-9226.
  • 5Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol, 2000, 65: 175-181.
  • 6Drayson M, Begum G,Basu S, et al. Effect of paraprotein heavy and light chain type and free light chain load on survival in myeloma : an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood, 2006, 108:2013-2019,
  • 7Facon T, Avet-Loiseau H, Guillerm G, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-mieroglobulin produce a powerful myeloma staging system for patients receiving high dose therapy. Blood, 2001, 97:1566-1571.

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部